Patent · US Active

Detection and use of antiviral resistance mutations

US9932646B2 · kind B2 · utility

0Cited by

2References

2Claims

0Family size

Assignee

ABL SA · LU

Inventors

Angeline Ingrid Bartholomeusz · Melbourne, AU
Stehpen Locarnini · Melbourne, AU
Anna Ayre · Melbourne, AU
Lilly Ka Wai Yuen · Melbourne, AU
Peter William Angus · Melbourne, AU
Joseph Sasadeusz · Melbourne, AU
Paul Desmond · Albert Park, AU
Hans Tillman Leipzig · Durham, US
Thomas Bock Tuebingen · Lörrach, DE
William Sievert · Sydney, AU
Sharon Lewin · Armadale, AU

Key dates

Filing date	Oct 14, 2014
Grant date	Apr 3, 2018
Priority date	—
Expiry date	Oct 14, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/156
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.